Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation

Anticoagulant Drugs Clinical Trial

Official title:

Discontinuation for Oral Anticoagulants During the First Year of Use in Patients With Atrial Fibrillation Covered by a Medical Insurance

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04133545
• Other study ID #: Protocol_3525
• Status: Active, not recruiting
• Start date: April 4, 2018
• Est. completion date: September 2020

Study information

• Verified date: October 2019
• Source: Hospital Italiano de Buenos Aires
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year

Description:

The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year of use after their initiation during hospitalization in patients covered by our health insurance plan.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 360
• Est. completion date: September 2020
• Est. primary completion date: September 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient older than 18 years of age covered by our Health Care Insurance Plan.

2. Indication for oral anticoagulation with an expected duration of use of no less than 1 year.

Exclusion Criteria:

1. Refusal to take part.

2. Use of oral anticoagulants within 6 months prior to admission.

3. Presence of mechanical prosthetic valve.

4. Chronic renal failure with creatinine clearance <30 mL/min (estimated using the MDRD formula).

Related Conditions & MeSH terms

• Anticoagulant Drugs
• Atrial Fibrillation
• Auricular Fibrillation

Locations

Country	Name	City	State
Argentina	Hospital Italiano de Buenos Aires	Buenos Aires

Sponsors (2)

Lead Sponsor	Collaborator
Hospital Italiano de Buenos Aires	Boehringer Ingelheim

Country where clinical trial is conducted

Argentina, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anticoagulant Discontinuation Rate	Anticoagulant Discontinuation Rate	One year
Secondary	Discontinuation Predictors	Discontinuation Predictors	One year